Flow of Patients Through the Trial

Slides:

Advertisements

Similar presentations

Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Trial profile Fox K et al. Lancet 2008;372:

Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

ASTEROID A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden References Nissen et al. Effect.

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results SJ Nicholls, GL Bakris, JJP Kastelein, V Menon,

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

PERISCOPE Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes Stephen J. Nicholls MBBS.

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Dual Lipid-Lowering Strategy With Ezetimibe.

Results of the GLAGOV Trial

NICE –CG 181 Continuum of CVD Risk and its treatment

Results of the GLAGOV Trial

Results of the CARAT Study

The American College of Cardiology Presented by Dr. Steven E. Nissen

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

The American Heart Association Presented by Dr. Steven E. Nissen

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Oxford Niacin Trial.

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

PAD Patients vs Post-ACS Patients:

Patient disposition for the double-blind study period.

The Safety and Efficacy of Full vs

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Trial profile John A Dormandy et al. Lancet 2005;366:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Shifting Currents in Hyperkalemia Management 2015 in Review

Shifting Currents in Hyperkalemia Management 2015 in Review

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Fig. 1. MAHALO clinical trial flowchart.

Hajer GR et al. Atherosclerosis 2009;202:216-24

Stephen J. Nicholls, MBBS, PhD; E

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Flow of Patients Through Trial

Study Participant Flow

Flow Diagram of the Trial Selection Process

Baseline Characteristics, Blood Pressures, and Laboratory Values

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Disposition of Patients in the Atherogenic Dyslipidemia Study

Characteristics of included studies

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Flow of study participants

Translating Data From Trial to Practice

Presentation transcript:

Flow of Patients Through the Trial Steven E. Nissen, et al. JAMA 2006;295: Published online

Baseline Patient Characteristics* Steven E. Nissen, et al. JAMA 2006;295: Published online

Laboratory Results (n = 346)* Steven E. Nissen, et al. JAMA 2006;295: Published online

Baseline and Follow-up Intravascular Ultrasound Results Steven E. Nissen, et al. JAMA 2006;295: Published online

Primary Efficacy Parameters in Prespecified Subgroups Steven E. Nissen, et al. JAMA 2006;295: Published online

Adverse Events, Drug Discontinuations, and Clinical End Points in the Safety Population (N = 507) Steven E. Nissen, et al. JAMA 2006;295: Published online

Example of Regression of Atherosclerosis in a Patient in the Trial Steven E. Nissen, et al. JAMA 2006;295: Published online

Relationship Between Mean Low-Density Lipoprotein Cholesterol Levels and Median Change in Percent Atheroma Volume for Several Intravascular Ultrasound Trials Steven E. Nissen, et al. JAMA 2006;295: Published online